Survival by Exposure to Biologic Agents (Bevacizumab, Cetuximab, Panitumumab, or Regorafenib)
| Median | ||||
| Interval (mo) | None | Received 1 | Received 2 | P |
| From diagnosis of primary | 48.9 (35.4–62.4) (n = 110) | 49.4 (43.1–55.7) (n = 287) | 47.5 (39.2–55.8) (n = 117) | 0.98 |
| From diagnosis of hepatic metastases | 33.2 (27.5–38.9) (n = 111) | 37.6 (33.3–41.9) (n = 288) | 42.0 (34.8–49.2) (n = 117) | 0.30 |
| From first 90Y treatment | 11.5 (6.3–16.7) (n = 114) | 12.9 (11.0–14.9) (n = 295) | 7.0 (4.9–9.1) (n = 117) | 0.001 |
| From hepatic metastases to 90Y | 11.1 (8.0–14.2) (n = 111) | 15.4 (13.4–17.4) (n = 288) | 27.6 (24.7–30.5) (n = 117) | <0.001 |
| From 90Y (no extrahepatic metastases) | 14.7 (8.7–20.8) (n = 90) | 15.4 (11.0–19.8) (n = 178) | 9.6 (5.8–13.4) (n = 57) | 0.113 |
| From 90Y (with extrahepatic metastases) | 7.6 (1.1–14.1) (n = 24) | 7.8 (6.2–9.4) (n = 117) | 4.5 (2.7–6.3) (n = 60) | 0.113 |
Ranges in parentheses are 95% CI.